Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors

A Workshop | Washington DC
July 16-17, 2018

Samir Khleif and Roger Dansey
Co-Chairs, Workshop Planning Committee
THANKS TO THE NATIONAL CANCER POLICY FORUM SPONSORS

Centers for Disease Control and Prevention
National Cancer Institute/National Institutes of Health
American Association for Cancer Research
American Cancer Society
American College of Radiology
American Society of Clinical Oncology
Association of American Cancer Institutes
Bristol-Myers Squibb
Cancer Support Community
CEO Roundtable on Cancer
Flatiron Health
Helsinn Therapeutics (U.S.), Inc.
LIVESTRONG Foundation
Merck
National Comprehensive Cancer Network
Novartis Oncology
Oncology Nursing Society
Pfizer, Inc.
The Forum provides a continual focus within the National Academies on cancer, addressing issues in science, clinical medicine, public health, and public policy that are relevant to the goal of reducing the cancer burden.
WORKSHOP PLANNING COMMITTEE MEMBERS

CO-CHAIRS: ROGER DANSEY & SAMIR KHLEIF

AMY ABERNETHY
EDWARD BENZ, JR.
GIDEON BLUMENTHAL
CHRISTOFFER BOSHOFF
OTIS BRAWLEY
CHRISTOPHER COGLE
LISA KENNEDY SHELDON

LEE KRUG
MARTIN MURPHY
DAVID REESE
RICHARD SCHILSKY
DAN THEODORESCU
GEORGE WEINER

NATIONAL CANCER POLICY FORUM STAFF
ERIN BALOGH
NICOLE KASTELIC
NATALIE LUBIN
CYNDI TRANG
SHARYL NASS
SESSION 1
Overview of PD-1/PD-L1 Therapy and Need for Combinations

SESSION 2
Role of Biomarkers in Developing PD-1/PD-L1 Combinations

SESSION 3
Clinical Trial Design Strategies

SESSION 4
Regulatory Challenges

SESSION 5
Precompetitive Data Sharing and Collaboration

SESSION 6
Stakeholder Perspectives on the Path Forward